Loading...

Purified anti-human CD8a Antibody

Pricing & Availability
Clone
RPA-T8 (See other available formats)
Regulatory Status
RUO
Workshop
IV T171
Other Names
T8, Leu2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
RPA-T8_Purified_060807
Human peripheral blood lymphocytes stained with purified RPA-T8, followed by anti-mouse IgGs FITC
  • RPA-T8_Purified_060807
    Human peripheral blood lymphocytes stained with purified RPA-T8, followed by anti-mouse IgGs FITC
Compare all formats
Cat # Size Price Save
301002 100 µg ¥11,000
Description

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
Chimpanzee, Baboon, Pigtailed Macaque, Sooty Mangabey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
CyTOF® - Verified
Costim, IHC - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
  5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
  6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
Product Citations
  1. Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed
  2. Dhariwala MO, et al. 2020. Cell Rep Med. 1:100132. PubMed
  3. Dubrovsky L, et al. 2020. MBio. 11:. PubMed
  4. Alpert A, et al. 2022. Cell Syst. 13:71. PubMed
  5. Lu X, et al. 2021. J Exp Med. 218: . PubMed
  6. Leader AM, et al. 2021. Cancer Cell. 39:1594. PubMed
  7. Glass MC, et al. 2022. Cell Rep. 39:110728. PubMed
  8. McCarthy EE, et al. 2022. Cell Rep. 39:110815. PubMed
  9. Feyaerts D, et al. 2022. Cell Rep Med. 3:100680. PubMed
  10. Poon MML, et al. 2023. Nat Immunol. 24:309. PubMed
  11. Alroqi F, et al. 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed
  12. Wagner J et al. 2019. Cell. 177(5):1330-1345 . PubMed
  13. Gao H, et al. 2021. J Virol. :. PubMed
  14. Draganov D, et al. 2021. NPJ Breast Cancer. 7:22. PubMed
  15. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  16. Jouand N, et al. 2018. PLoS Pathog. 14:e1007041. PubMed
  17. Thakral D, et al. 2008. J Immunol. 180:7431. PubMed
  18. Liu X, et al. 2022. STAR Protoc. 3:101310. PubMed
  19. Zhao L, et al. 2018. Nat Med. 24:1536. PubMed
  20. Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed
  21. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
  22. O'Boyle KC, et al. 2020. Methods Mol Biol. 2111:1. PubMed
  23. Kong R, et al. 2019. Cell. 178:567. PubMed
  24. Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed
  25. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
  26. Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed
  27. Speir M,et al. 2017. Sci Rep.. 10.1038/s41598-017-14690-5. PubMed
  28. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  29. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  30. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  31. Wastyk HC, et al. 2021. Cell. 184(16):4137-4153.e14. PubMed
  32. Yang Q, et al. 2020. J Immunol. 2331:204. PubMed
  33. Zheng Y, et al. 2022. iScience. 25:103785. PubMed
  34. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  35. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
  36. Nicolet BP, et al. 2017. J Immunol. 198:962. PubMed
  37. Silva–Cardoso SC, et al. 2017. J Immunol. 199:253. PubMed
  38. Majri SS, et al. 2018. J Immunol. 200:110. PubMed
  39. Schwabenland M, et al. 2021. Immunity. . PubMed
  40. Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed
  41. Simon S, et al. 2018. Front Immunol. 1.7375. PubMed
  42. Eriksson E, et al. 2017. Clin Cancer Res. 5.018055556. PubMed
  43. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  44. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  45. Ravell JC, et al. 2020. J Clin Invest. 130:507. PubMed
  46. Martin E, et al. 2020. JCI Insight. :5. PubMed
  47. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
RRID
AB_314120 (BioLegend Cat. No. 301002)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
Dendritic cells, NK cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD8a RPA-T8 FC
APC/Cyanine7 anti-human CD8a RPA-T8 FC
Biotin anti-human CD8a RPA-T8 FC
FITC anti-human CD8a RPA-T8 FC
PE anti-human CD8a RPA-T8 FC
PE/Cyanine5 anti-human CD8a RPA-T8 FC
PE/Cyanine7 anti-human CD8a RPA-T8 FC
Purified anti-human CD8a RPA-T8 FC,CyTOF®,Costim,IHC
Alexa Fluor® 488 anti-human CD8a RPA-T8 FC
Alexa Fluor® 647 anti-human CD8a RPA-T8 FC
Pacific Blue™ anti-human CD8a RPA-T8 FC
Alexa Fluor® 700 anti-human CD8a RPA-T8 FC
PerCP anti-human CD8a RPA-T8 FC
PerCP/Cyanine5.5 anti-human CD8a RPA-T8 FC
Brilliant Violet 421™ anti-human CD8a RPA-T8 FC,ICC
Brilliant Violet 570™ anti-human CD8a RPA-T8 FC
Brilliant Violet 605™ anti-human CD8a RPA-T8 FC
Brilliant Violet 650™ anti-human CD8a RPA-T8 FC
Brilliant Violet 711™ anti-human CD8a RPA-T8 FC
Brilliant Violet 785™ anti-human CD8a RPA-T8 FC
Brilliant Violet 510™ anti-human CD8a RPA-T8 FC
Purified anti-human CD8a (Maxpar® Ready) RPA-T8 FC,CyTOF®
Alexa Fluor® 594 anti-human CD8a RPA-T8 ICC,FC
PE/Dazzle™ 594 anti-human CD8a RPA-T8 FC
APC/Fire™ 750 anti-human CD8a RPA-T8 FC
TotalSeq™-A0080 anti-human CD8a RPA-T8 PG
TotalSeq™-B0080 anti-human CD8a RPA-T8 PG
TotalSeq™-C0080 anti-human CD8a RPA-T8 PG
Ultra-LEAF™ Purified anti-human CD8a RPA-T8 FC,CyTOF®,Costim,IHC
Spark Violet™ 423 anti-human CD8a Antibody RPA-T8 FC
Spark Red™ 718 anti-human CD8a RPA-T8 FC
Spark PLUS UV395™ anti-human CD8a RPA-T8 FC
Go To Top Version: 4    Revision Date: 08/24/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account